Extended Data Fig. 6: Impact of in vivo azacitidine treatment on Fc receptor expression on normal immune cells and U5 snRNP200 expression on AML cells.
(a) Quantification of inhibitory FcR CD32B and activating FcR CD16.2 expression on monocytes/macrophages in peripheral blood from mice engrafted with inversion 3 AML after 5 days of control (PBS) versus azacitidine treatment. n = 9 mice per group. Bar graphs represent ± SEM (p from unpaired t-test; left *** p = 0.0005 and *p = 0.05; right *** p = 0.0007 and ** p = 0.007). FcR = Fc Receptor. (b) Schematic of experiment to test the impact of in vivo treatment expression on expression of U5 snRNP200 on the surface of AML cells. (c) Median fluorescence intensity of U5 snRNP200 expression on CD45.2+ malignant cells in peripheral blood (left), bone marrow (middle), spleen (right). n = 9 mice per group. Bar graphs represent ± SEM (p from unpaired t-test; left **** p = <.0001 middle ***p = 0.0004, right *** p = 0.0006). (d) Representative FACS plot of U5 snRNP200 cell surface expression on malignant myeloid (CD45.2+ CD3− CD19−) bone marrow cells following in vivo treatment with control or azacitidine (as quantified in (c)).
